We hypothesized that de novo variants (DNV) might participate in the genetic determinism of sporadic early-onset Alzheimer disease (EOAD, onset before 65 years). We investigated 14 sporadic EOAD trios first by array-comparative genomic hybridization. Two patients carried a de novo copy number variation (CNV). We then performed whole-exome sequencing in the 12 remaining trios and identified 12 non-synonymous DNVs in six patients. The two de novo CNVs (an amyloid precursor protein (APP) duplication and a BACE2 intronic deletion) and 3/12 non-synonymous DNVs (in PSEN1, VPS35 and MARK4) targeted genes from a biological network centered on the Amyloid beta (Aβ) peptide. We showed that this a priori-defined genetic network was significantly enriched in amino acid-altering DNV, compared with the rest of the exome. The causality of the APP de novo duplication (which is the first reported one) was obvious. In addition, we provided evidence of the functional impact of the following three nonsynonymous DNVs targeting this network: the novel PSEN1 variant resulted in exon 9 skipping in patient's RNA, leading to a pathogenic missense at exons 8-10 junction; the VPS35 missense variant led to partial loss of retromer function, which may impact neuronal APP trafficking and Aβ secretion; and the MARK4 multiple nucleotide variant resulted into increased Tau phosphorylation, which may trigger enhanced Aβ-induced toxicity. Despite the difficulty to recruit Alzheimer disease (AD) trios owing to age structures of the pedigrees and the genetic heterogeneity of the disease, this strategy allowed us to highlight the role of de novo pathogenic events, the putative involvement of new genes in AD genetics and the key role of Aβ network alteration in AD.
INTRODUCTION
The genetic architecture of Alzheimer disease (AD) is still incompletely characterized. Rare autosomal dominant forms of early-onset Alzheimer disease (EOAD) are caused by mutations within three genes (APP (amyloid precursor protein), PSEN1 and PSEN2). In addition, genome-wide association studies have implicated common variants at~20 genetic loci. 1 Notably, with the exception of the ε4 allele of the APOE gene, these variants have a modest effect on AD risk (OR ranging from 0.77 to 1.22) . With the advent of whole-exome sequencing, which consists in the massive parallel sequencing of all protein-coding exons of a genome, it has become possible to interrogate low-frequency variants in casecontrol studies, and rare missense variants in TREM2 and PLD3 have been reported to increase risk for AD. 2, 3 However, despite these findings, it is acknowledged that a substantial part of the genetic component of the disease remains unidentified.
Recently, the impact of de novo mutations in common neuropsychiatric diseases including mental retardation, autism or schizophrenia has been highlighted by several studies. Together, these studies have provided arguments that germline mutations with large effect could account for a fraction of sporadic cases affected by these conditions. Consequently, a 'de novo' experimental design has become an attractive paradigm for the discovery of relevant genes in complex diseases. 4 Different types of de novo genomic events have been studied. Although earlier studies focused on copy number variations (CNVs), more recent whole-exome sequencing studies have allowed for the detection of de novo singleor multiple-nucleotide variants (MNV) and indels. It is now estimated that CNVs larger than 100 kb occur de novo in~1 of every 50 individuals, whereas each individual carries an average of one exonic de novo single-nucleotide variants. 5 These studies are based on the simultaneous analysis of the whole-exome sequence of a patient and of his/her unaffected parents in family trios to detect mutation (s) present in the patient but not in his/her parents. Owing to the age structure of AD pedigrees, such a design is difficult to apply when dealing with diseases affecting elderly subjects. We nevertheless succeeded in sampling 14 EOAD patients (age of onset younger than 65) with no history of the disease in firstor seconddegree relatives, and their living parents (Table 1) .
MATERIALS AND METHODS
For detailed methods see Supplementary Information.
Subjects
Patients were recruited by a French memory clinical network. Diagnoses (neuropathologically proven AD, n = 2; probable AD with evidence of the AD pathophysiological process, n = 12) were performed according to the NINCDS-ADRDA 6 criteria. Inclusion criteria are described in Supplementary Methods and the demographic characteristics and APOE genotypes of the sample are displayed in Table 1 . Only patients with no affected relative among firstor second-degree relatives were included in the study.
CNV analysis
High-resolution array-comparative genomic hybridization analysis was performed using the Human High-Resolution Discovery Microarray Kit 1 × 1 M (Agilent Technologies, Santa Clara, CA, USA) using standard protocols. All CNVs encompassing genes and not previously reported in large array-comparative genomic hybridization studies in the database of genomic variants (http://dgv.tcag.ca) were confirmed in patients and their inheritance was assessed by quantitative multiplex PCR of short fluorescent fragments (Supplementary Figure S1 ).
Exome sequencing
Exomes were captured using Agilent SureSelect Human All Exon kits. Final libraries were then sequenced on a HiSeq2000. Bioinformatic pipelines, detection of de novo mutations and confirmation by Sanger sequencing are described in Supplementary Methods.
Building the Aβ network
We performed extensive literature search using Pubmed (January 2014) to collect information linking a set of genes with Amyloid beta (Aβ) processing, aggregation, clearance or toxicity using as key words APP, Aβ and each of the subheaders of the gene list ( Supplementary Table S1 ). As a result, 1988 references in English language were initially selected based on titles and abstracts. Irrelevant genes were filtered out and additional candidates were identified from the body text of these references. Routine literature searches were subsequently used to maintain the data set and identify new interactors. We only retained genes for which experimental evidence based on cell or animal models had been published. No further exclusion criteria were used except for the Aβ toxicity category for which genes involved in non-specific late stages of cell death were not retained. Direct protein-protein interaction was not a prerequisite but was noted, when documented. For that purpose, data retrieved during this search were compared with the extensive list of APP interactors previously compiled by Perreau et al. 7 Testing for enrichment in de novo mutations of the Aβ network The objective was to test whether the Aβ network was enriched in de novo mutations among our 12 EOAD patients, compared with the expected relative mutation rate of this network in the general population, conditional on the total number of de novo mutations observed. We considered several candidates of the network relative baseline mutation rate, either based on the proportion of bases jointly covered at 20 × that fell within the Aβ network, or based on the proportion of variants (synonymous or missense, rare or of any minor allele frequency) carried by the unaffected parents that fell within the Aβ network.
We tested for the enrichment of the network in de novo mutations among AD patients using a one-sided binomial test and adopting the highest baseline estimation as reference to generate a P-value as conservative as possible.
Analysis of PSEN1-splicing mutation Total RNA was extracted from patient's peripheral mononuclear cells collected in PAXgene Blood RNA tubes (Qiagen, Hilden, Germany) and reverse-transcribed using the Verso cDNA synthesis kit (Fisher Scientific, Illkirch, France). WT and mutant alleles were amplified using the following primers: forward: 5′-TGGAATTTTGGTGTGGTGGG-3′ and reverse: 5′-CCAATCCAAGTT TTACTCCCCTT-3′.
Analysis of VPS35 L625P mutant The p.Leu625Pro (L625P) mutation was engineered into the GFP-VPS35 construct 8 using the QuikChange kit (Stratagene, Santa Clara, CA, USA) according to manufacturer's instructions. Two independent clones that contained the L625P mutation were used for subsequent experiments. For immunoprecipitation experiments, the GFP-VPS35 constructs were transiently transfected into HeLa cells, and WT and mutant forms of GFP-VPS35 were immunoprecipitated, analyzed by western blotting and detected using 125 I-protein A as previously described. [9] [10] [11] For immunofluorescence staining, HeLa cells transiently transfected with GFP-VPS35 constructs were fixed and stained 24 h post transfection as previously described. 12 Imaging was performed using either a Zeiss Axioplan epifluorescence microscope, or the Cellomics ArrayScan V automated microscope for automated microscopy. 10 Conformational dynamics of MARK4 WT and mutant The microtubule affinity-regulating kinase (MARK)4 sequence (Uniprot ID: Q96L34), was mutated (ΔG316, E317D) and threedimensional structure for both WT and mutant were predicted using a comparative modeling tool Modeler 9v11 embedded in Discovery Studio Suite. The crystal structure of MARK2 in active state (PDB ID: 3IEC) 13 was used as template, and predicted models were refined and validated, with ATP and Magnesium ion docked into the catalytic cleft using Glide module in Schrödinger Suite 14 to represent the functional state of protein. GROMACS v4.5.5 (ref. 15 ) molecular dynamics simulation suite was used to assess their stability and conformational dynamics, where root means square deviation and root means square fluctuation plots were taken as a measure of stability. Both mutant and WT-predicted models hold conventional DFG-in/αC-in mode with outward folding of T-loop favorable for binding downstream substrate proteins with due changes as a result of their mutation. Adenosine triphosphate binding was stabilized by coordinate bonds with Mg2 + and hydrogen bonds with K88 of P-loop and A138 of hinge region in the MARK4 catalytic cleft. The predicted models have maintained their structural stability (Supplementary Figure S6 ) in the given time scale and hence used to study the structural changes between mutant and WT MARK4.
Analysis of Tau Ser262 phosphorylation by WT and mutant MARK4
Plasmid encoding the full-length human MARK4 cDNA cloned into the pcDNA3 expression vector is a kind gift from Dr Alessandro Beghini. The mutant MARK4 was generated using the Site-Directed Mutagenesis kit XL-II (Agilent) according to manufacturer's instructions.
Plasmids encoding Tau and the MARK4 constructs were transiently transfected into HEK293 cells. Twenty-four hours after transfection, proteins were extracted and analyzed by western blotting. Blots were stained with antibodies directed against MARK4 (1:2000; Abcam, Cambridge, UK), total Tau (1:50000; Dako, Santa Clara, CA, USA), Tau-PhosphoSer262 (1:2000; Invitrogen, Illkirch, France) and Actin-2066 (1:10000; Sigma, Lyon, France). Differential Ser262 staining by WT or mutant MARK4 was compared using a paired t-test after log transformation of normalized staining values.
RESULTS
We searched for de novo variations in the index cases of these trios using a two-step procedure. First, these patients were screened for CNVs by high-resolution array-comparative genomic hybridization allowing for a resolution of about 10 kb. An average of 47 CNVs (range 25-59) was detected per patient, three in average corresponding to rare CNVs encompassing genes. Subsequent analysis of rare CNVs intersecting genes in patients and their parents by quantitative multiplex PCR of short fluorescent fragments showed that all but two of these variants were inherited. In patient EXT 773, we observed a 7.6 Mb de novo 21q21 duplication, which encompassed APP and 15 other genes (Figure 1a and Supplementary Figure S1 ). Patient EXT 804 bore a 12 kb de novo deletion involving the intron 1 of BACE2 (Figure 1b and Supplementary Figure S1 ), which does not overlap with any CNV reported in the database of genomic variants (URL: http:// dgv.tcag.ca/).
In the 12 remaining trios, we then conducted a whole-exome sequencing screening. We generated~4.5 Gb of sequence per individual with a mean depth of 96.88-fold on RefSeq coding exons and canonical splice sites (± 2 bp). At this depth of coverage, an average of 81 and 89.8% of RefSeq coding exons and splice sites were jointly covered by at least 20 high-quality reads among the three trio members for exomes captured with Agilent SureSelect Human All Exon V4+UTRs and V5 kits, respectively (Supplementary Figure S2 ). Among the 20 001 exonic and splicing variants observed in average per exome, we identified 15 de novo variants (DNVs) in seven individuals ( Table 2 ). All were confirmed by Sanger sequencing. The observed rate of de novo events per individual in the RefSeq protein coding exons was 1.25, corresponding to an exonic point mutation rate of 2.14 ×10 − 8 , in accordance with previous estimates. 16 The distribution of the number of DNVs per trio did not differ from the Poisson distribution (P = 0.86, with one expected DNV per individual). Among the 15 DNVs, we observed 3 synonymous and 12 amino-acid-altering DNVs, including 10 missense variants, 1 splice site variant and one MNV. With the exception of the PHKA2 p.Arg290His variant (found once in the 1000 Genomes cohort), none of them was present in variants databases. The non-synonymous to synonymous ratio was 3.33. Five of the 10 missense variants were classified as damaging by at least 2 of 3 prediction programs (SIFT, Polyphen2 and Mutation Taster) ( Table 2 ).
An Aβ-centered network It is widely recognized that the Aβ peptide, resulting from the sequential cleavage of the APP, has a key role in the pathogenesis of AD. 17 Therefore, to interpret the biological significance of the DNVs identified in our trios, we registered all genes whose protein product was known to interact with Aβ production, aggregation, clearance or synaptic toxicity. We undertook a manual curation to collate, via a comprehensive literature search, all relevant information. As a result, a list of 323 genes defining an Aβcentered network was defined ( Supplementary Table S1 ). Then, for each trio analyzed by whole-exome sequencing, we calculated the number of coding nucleotide positions/canonical splice sites successfully read at at least 20 × in all trio members, summed these numbers across the 12 trios and dichotomized them between positions corresponding to genes included or not within the network. Three non-synonymous/splice site DNVs (all predicted to be damaging) affecting the PSEN1, VPS35 and MARK4 genes were identified among the 7 483 907 base pairs jointly read at 20 × within the network, and nine (four predicted to be damaging) among the 351 165 260 base pairs outside the network. This corresponds to a significant enrichment of nonsynonymous/splice site DNVs within the network (P = 0.0018, odds ratio = 15.3 with 95% confidence interval (2.7;61.3), Fisher's exact test). When only considering variants predicted to be damaging, with three of seven non-synonymous/splice site DNVs hitting the network, the P-value was 0.0003, odds ratio = 34.5 with 95% confidence interval (5.1;203.3)). To ensure that this enrichment was not the consequence of a non-specific high rate of de novo mutations within the genes of the network, we applied the same procedure to synonymous DNVs. No enrichment in synonymous DNVs within the network's genetic surface was found (P = 1). We also verified that the proportion of jointly covered base pairs did not significantly differ in genes of the network compared with other genes (P = 0.7108, Mann-Whitney U-test). To further ensure that the enrichment was not artifactual, we finally computed several estimates for the expected relative de novo mutation rate of the network with respect to the entire exome in the general population (see methods and Supplementary Table S2 ). We estimated the expected relative de novo mutation rate of the network by the ratio of the variant burdens found within the network and in the whole-exome sequence among the parents. Four classes of variants, which could be affected differently by selective pressure and genetic drift, namely (i) synonymous, (ii) missense and splice variants, (iii) rare synonymous and (iv) rare missense and splice variants, were considered to obtain a variety of estimates. Compared with the highest estimation of the relative de novo mutation rate of the network, three hits among 12 within the network corresponded to a significant enrichment in our EOAD patients (P = 0.0032, binomial test). Omitting the trio bearing the PSEN1 mutation, with two out of nine mutations hitting the network, the effect remained significant (P = 0.0212). We conclude that the excess of DNVs among a set of genes a priori classified as etiologically relevant in our EOAD patients supports the hypothesis that rare mutations spread among genes of the Aβ network are involved in the genetic determinism of sporadic EOAD. Overall, when taking into account the APP duplication and the BACE2 intronic deletion, 9 out of 14 patients carried at least one de novo genetic variation, among which five of them affected a gene of the Aβ network ( Table 2 ). Note that we did not find arguments in favor of mosaicism for all de novo mutations (Supplementary Figure S1 ), suggesting that they all are germline events. We next focused on the biological consequences of these five variations.
Biological consequences APP duplication. The interpretation of the 21q21 duplication is straightforward. We had previously established that APP duplication, leading to a 1.5-fold increase in APP expression, 18 is a cause of AD with cerebral amyloid angiopathy. 19 Consistently, the neuropathological examination of this patient showed Braak stage VI AD lesions with prominent cerebral amyloid angiopathy. Although 15 other genes were involved in this duplication (Figure 1) , it is now well-established that the duplication of APP alone is sufficient to cause AD. 20 BACE2 deletion. The BACE2 deletion is located at the end of intron 1, and overlaps enriched H3K4Me3 and H3K27Ac histone marks (Figure 1c and Supplementary Figure S1 ), which are molecular correlates of promoters and enhancers, respectively. 21, 22 The BACE2 gene encodes a protease known both to degrade Aβ intracellularly and to lower Aβ level via a θ-secretase cleavage of APP leading to non-amyloidogenic processing. 23, 24 Therefore, reduced BACE2 expression is predicted to result in a proamyloidogenic effect. To investigate whether this deletion could have an effect on BACE2 expression, we performed reverse transcriptionquantitative multiplex PCR of short fluorescent fragments experiments on cultured fibroblasts of the patient and 10 control individuals (see Supplementary Methods) . Although BACE2 mRNA expression in the patient's fibroblasts was among the lowest measured in this sample, it was not possible to firmly conclude on the putative proamyloidogenic effect of this mutation because of the large inter-individual variability among controls (data not shown).
PSEN1 c.869-2A4G mutation. The c.869-2A4G PSEN1 mutation is located on the splice acceptor site of exon 9, and is thus predicted to lead to the exclusion of the exon. Reverse transcription-PCR experiments confirmed the skipping of exon 9, resulting in the introduction of a missense mutation (p.Ser290Cys) at the aberrant exon 8/10 splice junction (Supplementary Figure  S4) . The effect on protein structure is thus similar to that of the well-known c.869-1 G4T substitution, 25 whose pathological consequences on Aβ42 production have been examined in detail by Steiner et al. 26 VPS35 p.Leu625Pro mutation. The VPS35 protein assembles with the other vacuolar protein-sorting VPS29 and VPS26 to form the cargo-selective subcomplex of the retromer complex, which mediates endosomal protein sorting into the endosome-to-Golgi and endosome-to-cell surface recycling pathways. Notably, the retromer complex controls the localization of the membrane protein SorLA, which has a crucial role in APP recycling and Aβ lysosomal degradation. SorLA is encoded by the SORL1 gene, for which both rare and common variants have been associated with AD risk. 27, 28 In addition, the retromer cargo-selective subcomplex also functions as a hub for recruiting other machinery involved in endosomal protein sorting, including the WASH complex (comprising WASH1, strumpellin, FAM21, KIAA1033 and CCDC53), FKBP15 and TBC1D5. 29 A rare missense mutation of VPS35, p.Asp620Asn (D620N), has been found to cause Parkinson disease and results in impaired association of the retromer cargo-selective subcomplex with the WASH complex. 30, 31 The L625P mutation is located in the VPS35 C-terminal domain involved in VPS29 binding, similar to the D620N missense mutation. When HeLa cells were transiently transfected with a GFP-tagged VPS35 L625P mutant, the mutation reduced the amount of VPS29 that co-immunoprecipitates with the tagged VPS35 (Figure 2 ), although the effect was not as pronounced as that of the H675R mutation, a mutation initially characterized in Saccharomyces Cerevisiae that totally abolishes the binding to VPS29. 9 The ability of the L625P mutant to co-immunoprecipitates VPS26 also appeared compromised relative to WT VPS35 (Figure 2) . Interestingly, the L625P mutation exhibited strikingly different properties than the Parkinson disease-causing D620N mutation that binds VPS26 and VPS29 normally but associates weakly with FKBP15 and the WASH complex proteins FAM21 and strumpellin. By contrast, the L625P mutant could coimmunoprecipitate FKBP15 and the WASH complex similarly to WT VPS35. However, as the association of TBC1D5 with the retromer cargo-selective subcomplex depends on binding to VPS29, the reduced binding of VPS29 to the VPS35 L625P mutant also reduced the amount of TBC1D5 that co-immunoprecipitates with the GFP-tagged VPS35 L625P mutant (Figure 2 ). Consistent with these findings, when the cellular localization of the L625P mutant was examined, we observed that the association of VPS35 L625P to endosomes was markedly reduced compared with WT VPS35 or the D620N mutant (Supplementary Figure S5) . We Figure S5 . therefore conclude that the L625P mutant, acting by a mechanism different from the Parkinson disease-causing D620N mutation, behaves as a partial loss-of-function mutant that shows reduced ability to form functional complexes with both VPS29 and VPS26. To interpret this loss-of-function mechanism in the context of AD, we should remember that reduction of VPS35 expression has been shown to modulate APP processing in transgenic animals or cell cultures. Among the 11 studies addressing the role of loss of VPS35 function, 27, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] all but one concluded that a reduction in VPS35 expression resulted in increased Aβ production. as GSK3β and CdK5. 42 MARK4 appears to have a more pronounced role than other MARKs in this process. 43 The overexpression of MARK4 in primary cultures of rat hippocampal neurons leads to Tau hyperphosphorylation, reduced expression of synaptic markers and dendritic spine loss, a phenotype reminiscent of that observed after Aβ oligomer treatment. Furthermore, pharmacological inhibition of MARK kinases abrogated the toxic effects of Aβ oligomers on dendritic spines and synapses. 44 Accordingly, in drosophila models, Tau Ser262 phosphorylation is critical for Aβ42-induced Tau toxicity, 45 and PAR-1 kinase (the fly ortholog of MARKs) has an initiator role in the temporally ordered phosphorylation process that confers Tau toxicity. 46 Altogether, these data demonstrate that phosphorylation of Tau by PAR-1/MARK family kinases is a primary downstream event by which Aβ exerts its toxicity on synapses and dendritic spines.
The MARK4 double amino-acid change (ΔG316, E317D) caused by the MNV is located in a negatively charged short motif linker that resembles the common docking site in MAP kinases 47 and is known to tether the kinase to partners, that is, substrates or regulators. 48 To gain insight on the structural modifications induced by these changes, we predicted the three-dimensional structure of WT and mutant form of MARK4 kinase-ubiquitinassociated (UBA) domain in active form (see methods).
The two amino-acid changes did not modify the conformation of the common docking motif. However, they altered the structural arrangement of the common docking motif with respect to the above-lying helix HE of the C lobe. They increased the distance from the original 7.1 Å observed in WT form tõ 7.7 Å, thereby exposing the charged residues E315, E317 and E318, which would aid in strengthening the association of MARK4 with partner proteins (Figure 3a) . Superimposition of the kinase-UBA regions of mutant form with the WT active form displays drift in the position of N and C lobes, wherein the distance between the lobes is about 17.8 Å when mutated compared with 22.4 Å in WT form, signifying that they move toward the ATP-binding cleft. As a result, the interaction between ATP and the residues of the catalytic cleft is enhanced by the addition of several new interactions. In the WT, ATP forms hydrogen bonds with K88 and Y137, and in mutant form, in addition to these interactions, it forms hydrogen bonds with K67, G68, N69 of P-Loop, and with K102 of αC helix (Figure 3b and Supplementary Figure S6 ). Moreover, the T-Loop in the mutant model shows considerable displacement with reference to its native position observed in the WT model (Figure 3a) , which further increases the area of the substrate-binding region, facilitating a strong association of MARK4 with its associated proteins. These observations indicate that the mutation in the common docking motif tends to constrict the space between the N and C lobes, strengthens the association of ATP, and increases the volume of the substrate-binding cleft. These features are predicted to result in a stronger association between MARK4 and substrates, and an increase in phosphorylation activity.
To directly assess the consequence of the MARK4 MNV on Tau phosphorylation, we co-transfected HEK293 cells with Tau and either the WT or mutant MARK4 constructs and analyzed Tau Ser262 phosphorylation by western blotting (Figure 4a ). We observed a significant increase of Tau Ser262 phosphorylation (P = 0.01; paired t-test on log-transformed staining values) in cells transfected with the mutant compared to the WT construct ( Figure 4b ). We conclude that the MARK4 MNV results in a gain-offunction regarding the ability of MARK4 to phosphorylate Tau on Ser262.
DISCUSSION
In complex diseases such as autism or schizophrenia, despite the wealth of data recently generated, interpreting the role of de novo mutations remains challenging. These mutations are often retrieved as singletons and inferring causality necessitates the arduous identification of genes recurrently hit by disruptive mutations. 4 However, this requires hundreds or thousands of trios as illustrated by the few genes so far identified with certainty in huge studies (including~4500 trios) in autism spectrum disorder. 49, 50 Given the difficulty of identifying recurrently hit genes, these studies have focused on the demonstration that de novo mutations aggregate within particular biological pathways. [49] [50] [51] [52] In the context of EOAD, we took advantage of the large body of pathophysiological data accumulated in the past 20 years to define an a priori biological network containing potentially etiologically relevant genes. We show that this network is indeed significantly enriched in de novo mutations. Note that, as the delineation of the network is based on the current knowledge of Aβ biology, we cannot exclude that some genes hit by de novo mutations and listed as 'out of the network' are in fact genuine Aβ genetic interactors, which would lead to an even higher enrichment.
By sampling 14 EOAD sporadic cases, we detected two clearly pathogenic de novo events, known to be responsible for autosomal-dominant forms of the disease. It should be noted that this is the first de novo APP duplication reported so far and that only three proven PSEN1 de novo missense mutations had previously been reported in AD patients. [53] [54] [55] Mutations in sporadic AD cases have already been reported. However, it is necessary to confirm both parenthood and the absence of mutation in unaffected parents before claiming the de novo occurrence of a mutation. The parents are often deceased at the time of genetic analyses of their offspring, so that their DNA cannot be obtained. The role of de novo APP and PSENs causative events in sporadic EOAD is therefore probably underestimated. It should be noted that, given our limited sample size, no frequency data of de novo causative EOAD events should be inferred from this study.
For the APP duplication and the PSEN1 mutation, the functional consequences are well-known. For the other genes in the network, we undertook functional studies to demonstrate a significant effect of these mutations on relevant biological parameters. We succeeded for two genes. With VPS35 variation, our data support the role of the endosomal trafficking pathway in EOAD and underline the importance of the retromer genes in the genetic architecture of the disease. More importantly, in the context of current efforts to link Aβ pathology to Tau pathology in AD, we provide the first genetic evidence that MARK4, a gene coding for a kinase of Tau, is involved in AD pathogenesis. By increasing Tau phosphorylation at position 262, this mutation is predicted to favor detachment of Tau from the microtubule network. Whether this mutation acts synergistically with Aβ exposition to promote Tau pathology or totally bypasses it remains to be established.
Despite these functional arguments and contrary to the APP duplication and the PSEN1 mutation, which are currently considered as fully penetrant mutations, no definite conclusion should be drawn regarding the penetrance of the VPS35 and the MARK4 mutations, in the absence of segregation data in the next generations. Indeed, as the onset of AD appears after the reproduction age, we may expect transmission of these rare variants. Thus, searching for the potential implication of rare variants in the genes hit by DNVs in this work in unexplained familial cases could be promising but will require huge sample sizes in a case-control setting or large pedigrees.
Owing to the age structure of AD pedigrees it was not possible to include late-onset AD cases in our sample. The question of whether de novo mutations also affect a subset of late-onset AD cases or will by necessity manifest with earlier onset disease cannot be addressed. We can only speculate that some de novo mutations might result in a late expression of AD. Indeed, some late-onset AD cases are sporadic and have parents deceased in an advanced age without AD. This could be consistent with the contribution of a de novo mutation, but also of incompletely penetrant inherited variants or of environmental factors.
In conclusion, our data support the validity of the family trio strategy. They reinforce the conclusions drawn in mental retardation, another condition for which sufficient knowledge of the underlying biological pathways allowed to establish causality for a large subset of de novo mutations identified in a family trio screen. 56 More generally, as the understanding of the pathophysiological grounds of complex diseases improves, this study design combining a network-based analysis with biological validation of variants will most likely become a choice strategy to identify etiologically relevant rare variants spread among a large collection of genes.
